Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). However, the prevalence and prognostic significance of preexisting CVD in Japanese patients with advanced CKD have not been fully elucidated. We investigated the prevalence of CVD and its association with end-stage kidney disease (ESKD) and death using data from the nationwide, multicenter, prospective REACH-J-CKD cohort study.
The REACH-J-CKD study enrolled 2,249 adult patients with CKD stages G3b–G5 who were not on dialysis and were treated by nephrologists at 31 centers across Japan. Baseline comorbidities were recorded, including coronary artery disease, arrhythmia, heart failure, cerebrovascular disease, and non-coronary arterial disease (including aortic, renal, or peripheral artery disease). We examined the prevalence of CVD according to age, sex, CKD stage, and cause of CKD, as well as cardiovascular risk factors such as hypertension, dyslipidemia, diabetes, obesity, and smoking. The primary outcome was ESKD (initiation of dialysis or kidney transplantation) or all-cause death during a 5-year follow-up. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models adjusted for age, sex, body mass index, eGFR, and diabetes.
The mean ± SD age was 69.0 ± 12.6 years; 64.7% were men; and the mean eGFR was 23.2 ± 10.4 mL/min/1.73 m². The numbers of patients in CKD stages G3b, G4, and G5 were 632, 1,011, and 606, respectively. Causes of CKD included diabetic kidney disease (22.0%), hypertensive nephrosclerosis (27.4%), glomerulonephritis (24.2%), and others (26.4%). Cardiovascular risk factors were highly prevalent: hypertension (87.9%), diabetes (33.8%), dyslipidemia (51.6%), obesity (30.3%), and current or past smoking (53.9%). Overall, 39.4% had at least one CVD, consisting of coronary artery disease (12.7%), arrhythmia (12.0%), heart failure (7.8%), cerebrovascular disease (14.1%), and arterial disease (8.5%). The prevalence of CVD increased with age and CKD stage. During follow-up, ESKD occurred in 37.5% of patients with CVD and 38.4% without CVD, whereas death occurred in 20.7% with CVD and 8.7% without CVD. In Cox regression analyses, preexisting CVD was significantly associated with death (unadjusted HR 3.39, 95% CI 2.54–4.53, p < 0.001; adjusted HR 2.20, 95% CI 1.61–3.00, p < 0.001), but not with progression to ESKD.
Among Japanese patients with advanced CKD, approximately 40% had a history of CVD. Preexisting CVD was independently associated with mortality but not with ESKD. These findings underscore the importance of intensive management of cardiovascular risk and prevention of fatal cardiovascular events in patients with advanced CKD before progression to kidney failure.
